SCHEMBL2536640

SCHEMBL2536640

O=Cc1c[nH]c2cccc(-c3ccccc3)c12

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.58
IMPDH2 P12268 1/20 0.51
PLK4 O00444 1/20 0.47
MAPK9 P45984 1/20 0.47
LIMK1 P53667 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
AKT3 Q9Y243 1/20 0.47
HTR2A P28223 1/20 0.46
PIM1 P11309 2/20 0.39
PIM3 Q86V86 2/20 0.39
PIM2 Q9P1W9 2/20 0.39
PARP1 P09874 3/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
METAP2 P50579 1/20 0.37
TRIM24 O15164 1/20 0.36
TRIM33 Q9UPN9 1/20 0.36
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954181 0.86 CYP2A6 (0.54) CYP2A6IMPDH2PIM1PIM3PIM2
SCHEMBL671445 0.86 CYP2A6 (0.54) CYP2A6IMPDH2MAPK9CLK4PIM1
SCHEMBL15332050 0.83 CYP2A6 (0.51) CYP2A6IMPDH2CLK4PIM1PIM3
SCHEMBL1430067 0.82 ALDH1A1 (0.50) CYP2A6IMPDH2PLK4PARP1CDK4
SCHEMBL29956756 0.82 CYP2A6 (0.50) CYP2A6IMPDH2PIM1PIM3PIM2
SCHEMBL10622395 0.82 CYP2A6 (0.50) CYP2A6IMPDH2PIM1PIM3PIM2
SCHEMBL1429453 0.81 CYP2A6 (0.49) CYP2A6IMPDH2PLK4AKT3PIM1
SCHEMBL15331057 0.81 CYP2A6 (0.55) CYP2A6IMPDH2HTR2APIM1PIM3
SCHEMBL7331481 0.80 CYP2A6 (0.46) CYP2A6IMPDH2PARP1NPC1RAB9A
SCHEMBL29952428 0.78 CYP2A6 (0.70) CYP2A6IMPDH2PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-63063657-A None JP disclosed
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
JP-S6363657-A INDOLE DERIVATIVE AND PRODUCTION THEREOF KISSEI PHARMACEUT CO LTD 1988-03-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B CYP2A6 202/4885IMPDH2 1292/4885PLK4 3463/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CYP2A6 202/4885IMPDH2 1292/4885PLK4 3463/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B CYP2A6 202/4885IMPDH2 1292/4885PLK4 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.